Is compounded semaglutide from a telehealth provider safe?

Compounded semaglutide is not FDA-approved, meaning its potency, sterility, and inactive ingredients have not been federally verified. The FDA has issued warnings about dosing errors and contamination risks with compounded GLP-1 products. It may be a short-term option during verified drug shortages, but it should not be your first choice if branded medication is available and accessible.

Do I need a in-person visit to get a GLP-1 prescription via telehealth?

In most U.S. states, a telehealth video or live audio consultation is legally sufficient for an initial prescription of a non-controlled medication like semaglutide. However, state laws vary, and some platforms use asynchronous (text/questionnaire-only) models that may not meet your state's standard of care. Always confirm the provider operates within your state's telehealth prescribing rules.

What are the FDA-approved GLP-1 medications for weight management specifically?

As of 2025, FDA-approved options for chronic weight management include semaglutide 2.4 mg weekly injection (Wegovy), tirzepatide 2.5–15 mg weekly injection (Zepbound), and liraglutide 3 mg daily injection (Saxenda). Ozempic and Mounjaro are FDA-approved for type 2 diabetes and are sometimes prescribed off-label for weight loss—this is legal but means less regulatory oversight of that specific use.

How do I know if a telehealth provider is legitimate?

Look up the medical group or physician name on your state's medical board website to confirm active licensure and no disciplinary actions. Legitimate providers will also have a clear privacy policy, a disclosed physical business address, and transparent refund or cancellation terms. If you cannot identify the prescribing clinician before paying, treat that as a disqualifying red flag.

Will my insurance cover GLP-1 medication prescribed through a telehealth provider?

Coverage depends on your insurance plan, diagnosis coding, and whether the provider bills insurance. Many commercial plans cover Wegovy or Zepbound for obesity (BMI ≥30, or ≥27 with a comorbidity) when prescribed by a participating provider. Medicare Part D currently does not cover weight-loss drugs, though this may change. Always verify your specific plan benefits before committing to a provider.

Buyer guide · Weight Loss

How to Choose a GLP-1 Telehealth Provider

GLP-1 receptor agonists—medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—have changed the clinical landscape for weight management. Telehealth has made accessing these drugs faster and more convenient, but the market is flooded with providers ranging from rigorous medical practices to bare-minimum prescription mills. This guide walks you through exactly what to evaluate before handing over your credit card: licensing, clinical oversight, drug sourcing, cost transparency, and ongoing support. If your BMI is under 27, you have no weight-related comorbidities, and your doctor has already said medication isn't appropriate for you, you can skip this category entirely.

By HealthNation Editorial

What to look for

1
FDA-Approved Drug Pathway
Why it matters: Only FDA-approved branded GLP-1 medications (Wegovy, Zepbound, Saxenda, etc.) have undergone the full safety and efficacy review process required for chronic weight management.
What to look for: Confirm the provider explicitly prescribes FDA-approved brand-name drugs as their primary pathway. Be cautious of providers whose entire business model centers on compounded semaglutide or tirzepatide—compounded versions are not FDA-approved and their safety and potency are not federally verified.
2
Licensed Prescriber and State Compliance
Why it matters: A prescription for a controlled or high-risk metabolic medication must come from a licensed clinician legally authorized to prescribe in your state.
What to look for: Look for the prescriber's credentials (MD, DO, NP, PA with appropriate oversight), the state(s) they are licensed in, and whether the platform discloses its medical group name. You should be able to verify the prescriber on your state's medical board website before your first appointment.
3
Comprehensive Intake and Ongoing Monitoring
Why it matters: GLP-1 medications carry real side effects and contraindications; a provider who skips clinical evaluation is cutting corners that could harm you.
What to look for: The intake process should include a detailed health history (including personal or family history of thyroid cancer or pancreatitis), current medications review, and baseline labs or a requirement that you obtain them. Ongoing check-ins—at minimum every 90 days—should be part of the service.
4
Transparent, All-In Pricing
Why it matters: Hidden fees for consultations, titration changes, or prior-authorization support can make a seemingly cheap service far more expensive than advertised.
What to look for: The website should clearly state the monthly or quarterly cost, what is included (consultation, messaging, PA support, dose adjustments), and whether medication cost is separate. Ask specifically whether insurance billing is available and whether they will help with manufacturer savings cards.
5
Insurance and Prior Authorization Support
Why it matters: Branded GLP-1 medications can cost $900–$1,400 per month out-of-pocket, so insurance coverage is the difference between sustainable and unaffordable treatment.
What to look for: Providers should offer to bill insurance, assist with prior authorization appeals, and connect you with manufacturer patient-assistance programs. Avoid platforms that explicitly discourage insurance use or make no mention of coverage support.
6
Lifestyle Support Infrastructure
Why it matters: Clinical evidence shows that GLP-1 medications work best alongside behavioral support; a provider that offers only a prescription is delivering below standard-of-care.
What to look for: Look for access to registered dietitians, health coaches, or structured nutrition and activity curricula—even if offered as an add-on. The platform should not frame medication as a standalone solution.

Red flags — skip products that…

×Avoid providers that offer a prescription after only a short asynchronous questionnaire with no live or video clinical encounter, especially for first-time GLP-1 patients.
×Skip platforms that sell only compounded semaglutide or tirzepatide and do not offer or discuss FDA-approved branded alternatives—this signals a business model, not a clinical model.
×Be wary of any service that advertises 'no prior authorization needed' as a feature without explaining that this means you will pay full out-of-pocket cash price indefinitely.
×Avoid providers that cannot tell you the name, credentials, and state license of the clinician who will be signing your prescription.
×Skip any platform using aggressive discount-countdown timers, celebrity endorsements as medical evidence, or language like 'guaranteed weight loss'—these are marketing tactics, not clinical standards.

Our picks are coming online

We're testing specific products against the criteria above. As reviews go live they appear here. The criteria above are the rubric we use — you can buy from any retailer with confidence as long as the product meets them.

Email me when picks land

Why this category matters (and when it doesn't)

GLP-1 receptor agonist medications represent a genuine shift in how clinicians can support weight management. In large randomized trials, semaglutide 2.4 mg produced mean body weight reductions of approximately 15% over 68 weeks compared to placebo (Wilding et al., 2021), and tirzepatide produced reductions of up to 22.5% in a separate phase 3 trial (Jastreboff et al., 2022). These are meaningful numbers by any clinical standard.

Telehealth has expanded access to these medications for people who live far from obesity medicine specialists, have limited time for in-person visits, or face long wait times in the traditional healthcare system. That access is genuinely valuable. The problem is that the convenience model has attracted providers whose primary interest is subscription revenue, not clinical outcomes. Choosing the wrong provider can mean receiving a substandard clinical workup, paying for a drug that isn't what it claims to be, or losing access to coverage support that could save you hundreds of dollars a month.

You should skip this category entirely if: your BMI is below 27, your primary care physician has evaluated you and concluded medication is not appropriate, you are pregnant or planning pregnancy, or you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (both are contraindications listed in FDA labeling).

How we evaluate

We assess GLP-1 telehealth providers across six dimensions, listed in priority order in the criteria section above. The non-negotiables are FDA-approved drug pathways and verified licensed prescribers in your state. Everything else—pricing, lifestyle support, insurance help—matters, but it matters less than the basic clinical and legal foundation of the service.

We do not accept provider payments to influence rankings. We have not yet verified specific brands; product picks will be added separately once our vetting process is complete. This guide gives you a checklist you can apply to any provider you encounter.

GLP-1 medications in plain English

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating. It signals the pancreas to release insulin, slows gastric emptying (so you feel full longer), and acts on brain regions that regulate appetite and reward. GLP-1 receptor agonists are synthetic molecules that mimic and extend this hormone's effects.

These are not appetite suppressants in the traditional stimulant sense. They do not increase heart rate or cause the jitteriness associated with older weight-loss drugs. Their primary side effects are gastrointestinal—nausea, vomiting, constipation, diarrhea—especially during dose escalation. Rare but serious risks include pancreatitis and, based on rodent studies (not confirmed in humans at therapeutic doses), thyroid C-cell changes. Patients with relevant personal or family history should not use these medications.

A key clinical point: GLP-1 medications suppress appetite and support weight loss while you take them. Research indicates that weight regain is common after discontinuation (Wilding et al., 2022), which means this is likely a long-term or indefinite treatment for most patients—making provider quality and sustainable pricing more important, not less.

Dose and timing

All currently FDA-approved injectable GLP-1 medications for weight management use a dose-escalation schedule designed to minimize gastrointestinal side effects. Wegovy (semaglutide), for example, starts at 0.25 mg weekly and increases every four weeks over approximately five months to the maintenance dose of 2.4 mg weekly. Zepbound (tirzepatide) follows a similar stepwise escalation. Rushing through escalation to reach the maintenance dose faster is a patient safety issue, not a scheduling preference.

Your telehealth provider should have a clear clinical protocol for dose escalation and should offer easy access to a clinician if you experience side effects that make dose escalation difficult. Providers who auto-refill at the next dose tier without any check-in are not providing adequate oversight.

Timing of injections is flexible (same day each week, any time of day), and injections can be given in the abdomen, thigh, or upper arm. Your provider should offer or direct you to injection training resources, especially if you have no prior experience with self-injection.

Who should skip

Beyond the contraindications already noted, you should approach this category with extra caution or skip it if:

You have a history of eating disorders—GLP-1-induced appetite suppression can interact unpredictably with disordered eating patterns, and you need a provider with behavioral health expertise.
You are on insulin or other glucose-lowering medications for type 2 diabetes—dose adjustments are typically needed and require closer medical supervision than most telehealth platforms provide.
You have a history of severe gastrointestinal disease, including gastroparesis—GLP-1 medications further slow gastric emptying and are generally contraindicated.
You cannot afford or access the medication long-term—starting a treatment you will need to stop due to cost in three months is not a neutral decision; weight regain is well-documented upon discontinuation.

Bottom line

The best GLP-1 telehealth provider is the one that prescribes FDA-approved medications, employs verifiably licensed clinicians, conducts a real clinical intake, supports you through insurance and prior authorization, and checks in with you regularly. None of these are luxury features—they are the floor of acceptable medical care.

Use the checklist in this guide before your first consultation. Ask every provider the same questions: Who will be prescribing for me? What is their license number? Do you prescribe branded FDA-approved medications? How do you handle prior authorization? What happens if I have side effects between check-ins? A quality provider will answer these questions directly. A provider that deflects or cannot answer should not receive your business or your health history.

We will say plainly: we don't yet know which specific telehealth platforms will maintain quality standards over the next two to three years as this market consolidates. That is why this guide equips you to evaluate any provider, rather than directing you to a single name.

References

Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725

Frequently asked

Is compounded semaglutide from a telehealth provider safe?: Compounded semaglutide is not FDA-approved, meaning its potency, sterility, and inactive ingredients have not been federally verified. The FDA has issued warnings about dosing errors and contamination risks with compounded GLP-1 products. It may be a short-term option during verified drug shortages, but it should not be your first choice if branded medication is available and accessible.
Do I need a in-person visit to get a GLP-1 prescription via telehealth?: In most U.S. states, a telehealth video or live audio consultation is legally sufficient for an initial prescription of a non-controlled medication like semaglutide. However, state laws vary, and some platforms use asynchronous (text/questionnaire-only) models that may not meet your state's standard of care. Always confirm the provider operates within your state's telehealth prescribing rules.
What are the FDA-approved GLP-1 medications for weight management specifically?: As of 2025, FDA-approved options for chronic weight management include semaglutide 2.4 mg weekly injection (Wegovy), tirzepatide 2.5–15 mg weekly injection (Zepbound), and liraglutide 3 mg daily injection (Saxenda). Ozempic and Mounjaro are FDA-approved for type 2 diabetes and are sometimes prescribed off-label for weight loss—this is legal but means less regulatory oversight of that specific use.
How do I know if a telehealth provider is legitimate?: Look up the medical group or physician name on your state's medical board website to confirm active licensure and no disciplinary actions. Legitimate providers will also have a clear privacy policy, a disclosed physical business address, and transparent refund or cancellation terms. If you cannot identify the prescribing clinician before paying, treat that as a disqualifying red flag.
Will my insurance cover GLP-1 medication prescribed through a telehealth provider?: Coverage depends on your insurance plan, diagnosis coding, and whether the provider bills insurance. Many commercial plans cover Wegovy or Zepbound for obesity (BMI ≥30, or ≥27 with a comorbidity) when prescribed by a participating provider. Medicare Part D currently does not cover weight-loss drugs, though this may change. Always verify your specific plan benefits before committing to a provider.

HealthNation publishes informational content, not medical advice. We may earn a commission from purchases via merchant links on this page. See our affiliate disclosure and medical disclaimer.

What to look for

FDA-Approved Drug Pathway

Licensed Prescriber and State Compliance

Comprehensive Intake and Ongoing Monitoring

Transparent, All-In Pricing

Insurance and Prior Authorization Support

Lifestyle Support Infrastructure